ABBV vs ANET: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Arista Networks, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-05.
AbbVie Inc. · Healthcare
$197.69
+6.3% upside to fair value
Grade C
High Quality
VS
Arista Networks, Inc. · Technology
$172.62
+12.4% upside to fair value
Grade C
High Quality
QuantHub Verdict
ANET has more upside to fair value
(+12.4%).
ANET trades at a lower forward P/E
(61.8x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
ANET |
| Current Price |
$197.69 |
$172.62 |
| Fair Value Estimate |
$210.22 |
$193.98 |
| Upside to Fair Value |
+6.3%
|
+12.4%
|
| Market Cap |
$349.7B |
$217.4B |
| Forward P/E |
83.3x
|
61.8x
|
| EV / EBITDA |
23.4x
|
54.8x
|
| Price / Sales |
5.7x
|
24.1x
|
| Price / FCF |
18.7x
|
51.1x
|
| Revenue Growth YoY |
+10.0%
|
+28.9%
|
| Gross Margin |
70.2%
|
64.1%
|
| Operating Margin |
26.7%
|
42.8%
|
| Return on Equity |
-361.6%
|
31.0%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
5.35%
|
1.96%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology, neuroscience, oncology, and aesthetics. The company benefits from a durable competitive moat driven by blockbuster drugs such as Skyrizi and Rinvoq, which are experiencing rapid growth and offsetting declines from Humira due to biosimilar competition. Despite a high trailing and forwa…
Arista Networks is a leading provider of software-driven cloud networking solutions focused on AI, cloud, and data center markets. The company benefits from durable competitive advantages including a highly experienced leadership team led by CEO Jayshree Ullal, who has driven growth from startup to a $100 billion market cap S&P 500 company. Arista's business quality is high, supported by strong r…
Accumulation Zones
| Metric |
ABBV |
ANET |
| Zone Low |
$157.66 |
$145.48 |
| Zone High |
$178.69 |
$164.88 |
| In Buy Zone? |
No
|
No
|